Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ROL stock price vs LH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LH's multiple
Needs LH P/E.
Implied fair value · at ROL's multiple
Needs ROL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ROLLINS, INC. · implied price per share
Bear
$14.27
Base
$16.97
Bull
$20.49
LABCORP HOLDINGS INC. · implied price per share
Bear
$94.57
Base
$113.84
Bull
$148.04
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ECOLAB INC.
ROL vs ECL
HOME DEPOT, INC.
ROL vs HD
Serve Robotics Inc. /DE/
ROL vs SERV
CINTAS CORP
ROL vs CTAS
IRON MOUNTAIN INC
ROL vs IRM
MAXIMUS, INC.
ROL vs MMS
THERMO FISHER SCIENTIFIC INC.
ROL vs TMO
DANAHER CORP /DE/
ROL vs DHR
QUEST DIAGNOSTICS INC
ROL vs DGX
WEST PHARMACEUTICAL SERVICES INC
ROL vs WST
BAXTER INTERNATIONAL INC
ROL vs BAX
MCKESSON CORP
ROL vs MCK
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ROL can sustain its 11.0% growth, 19.3% operating margin, and 38.5% ROIC, then holding or accumulating on weakness is defensible because its premium to LH is backed by superior profitability and lower leverage even though relative valuation points to downside.
ROL trades well above LH on both earnings and sales multiples, and LH-based implied price of $29.91 suggests about 31.1% downside from the current $43.38. The gap is driven by ROL's much richer P/E, EV/EBITDA, and EV/Revenue multiples despite stronger operating performance.
Supporting Metrics
